Tirzepatide (100 mg)

What is Tirzepatide (100mg)?

Tirzepatide (100mg) is a synthetic peptide supplied as a research-grade lyophilized powder intended for laboratory studies of incretin biology, energy balance, and glucose metabolism. It is a 39-residue acylated peptide engineered to act as a dual agonist at glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) pathways. It has been studied for its effects on glycemic markers and body weight in many experimental settings. Key identifiers include:

• CAS Number: 2023788-19-2
• Chemical Formula: C₂₂₅H₃₄₈N₄₈O₆₈
• Molecular Weight: 4813.48 g/mol

It is also documented in research literature under the names P1206, LY3298176, tirzepatida, tirzepatidum, and OYN3CCI6QE. Tirzepatide is commonly produced with high purity (≥98–99%), verified by HPLC and mass spectrometry (MS).

What are the key features of Tirzepatide (100mg)?

• Dual incretin co-agonist (GIP + GLP-1 pathways) for metabolic research
• 39-residue peptide with Lys-linked C20 fatty diacid for extended half-life
• High purity (≈98–99%) and supplied as a 100 mg lyophilized vial
• Used in studies of glycemic control, appetite regulation, and body-weight dynamics
• Compatible with in-vitro signaling assays, pharmacokinetic testing, and rodent or large-animal models
• For laboratory research use only

How is Tirzepatide (100mg) synthesized?

Tirzepatide is synthesized by solid-phase peptide synthesis (SPPS), enabling precise assembly of the 39-residue backbone and side-chain modifications. After chain assembly, the lipid (C20) diacid is coupled to the Lys20 side chain via a linker to produce the acylated analog. Purification is achieved by preparative HPLC, and identity and composition are verified by high-resolution mass spectrometry and peptide mapping. Release testing commonly includes HPLC purity, MS confirmation of molecular weight, and checks for related impurities to ensure batch consistency for research use.

What is Tirzepatide (100mg) being studied for? What are its possible benefits?

Tirzepatide has been studied in preclinical and experimental research examining the relationship between growth hormone signaling, metabolism, and body composition. Preclinical research has explored how GIP and GLP-1 analogs may influence visceral adipose tissue, metabolic markers, and circulating IGF-1 levels. Some of the possible research areas are:

• Glucose homeostasis and insulinotropic responses in diabetes models
• Appetite and energy-balance regulation in obesity research
• Pharmacokinetic/pharmacodynamic profiling for long-acting incretin agents
• Comparative mechanistic studies versus GLP-1–only analogues

Experimental observations include:

• Changes in glycemic indices
• Alterations in food intake patterns
• Body weight changes in experimental systems

These outcomes are model-dependent and remain specific to controlled preclinical research environments.

How does Tirzepatide (100mg) work in research studies?

Tirzepatide delivers dual incretin signaling: portions of the peptide mimic GIP activity, while other regions support GLP-1–like actions. This results in glucose-dependent modulation of insulin and glucagon secretion, as well as neural signals that affect appetite and feeding. The lipid side chain promotes reversible albumin binding, slowing clearance and enabling prolonged receptor exposure in vivo. Researchers use Tirzepatide to dissect how combined incretin activation alters pancreatic, hepatic, and central nervous system pathways involved in metabolism.

What dosing information exists for Tirzepatide (100mg)?

Preclinical dosing of Tirzepatide varies depending on species, study objectives, and experimental models. In rodent studies, subcutaneous or intraperitoneal dosing is commonly used across a range of nmol/kg values to characterize pharmacokinetics, food-intake suppression, and metabolic responses. In vitro assays typically apply nanomolar concentrations to measure receptor activation and signaling. No standardized human dosing guidelines exist for research-grade Tirzepatide (100mg); dosing should be determined based on study objectives and ethical approvals.

How should Tirzepatide (100mg) be stored and handled?

• Store lyophilized vials at ≤–20 °C, protected from light and moisture.
• For short-term use, refrigerated storage at 2–8 °C is acceptable.
• Avoid repeated freeze–thaw cycles; aliquot reconstituted solution when needed.
• Brief room-temperature exposure during transport is acceptable if the cold chain is restored.
• Unopened lyophilized vials often remain stable for 24 months under proper storage conditions.

Where can I read more research about Tirzepatide (100mg)?

1. Sun B, Willard FS, Feng D, et al. Structural determinants of dual incretin receptor agonism by tirzepatide. Proceedings of the National Academy of Sciences. 2022;119(13):e2116506119. doi:10.1073/pnas.2116506119
2. Geisler CE, Antonellis MP, Trumbauer W, et al. Tirzepatide suppresses palatable food intake by selectively reducing preference for fat in rodents. Diabetes Obes Metab. 2023;25(1):56-67. doi:10.1111/dom.14843
3. Wang L. Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP. Drug Des Devel Ther. 2022;16:1547-1559. Published 2022 May 25. doi:10.2147/DDDT.S358989
4. National Center for Biotechnology Information. PubChem Compound Summary for CID 163285897, CID 163285897. https://pubchem.ncbi.nlm.nih.gov/compound/163285897
5. Willard FS, Douros JD, Gabe MBN, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17). doi:10.1172/jci.insight.140532

Compliance Statement

This product is intended for laboratory research use only and is not approved for human or veterinary use.